FORM D

Notice of Exempt Offering of Securities

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.



1. Issuer's Identity			
CIK (Filer ID Number)	Previous Name(s)	None None	Entity Type
0000910267			Corporation
Name of Issuer	_		C Limited Partnership
TITAN PHARMACEUTICALS INC			C Limited Liability Company
Jurisdiction of Incorporation/Organization			C General Partnership
DELAWARE	]		C Business Trust
Year of Incorporation/Organizatio	n		C Other
• Over Five Years Ago			
• Within Last Five Years (Specify Year)			

C Yet to Be Formed

# 2. Principal Place of Business and Contact Information Name of Issuer ITTAN PHARMACEUTICALS INC Street Address 1 Street Address 2 Id00 OYSTER POINT BLVD State/Province/Country ZIP/Postal Code Phone No. of Issuer SAN FRANCISCO CALIFORNIA

# 3. Related Persons

Last Name	First Name		Middle Name	
Rubin	Marc			
Street Address 1		Street Address 2	-	
400 OYSTER POINT BLVD		SUITE 505		
City	State/Province/Cou	ntry	ZIP/Postal Code	
SAN FRANCISCO	CALIFORNIA		94080	
Relationship: Execut	ive Officer	Director	Promoter	
Clarification of Response (if Necessary) Executive Chairman				
Last Name	First Name		Middle Name	
DeVarney	Katherine		Beebe	
Street Address 1	Street Address 2			
400 OYSTER POINT BLVD		SUITE 505		
City	State/Province/Cou	ntry	ZIP/Postal Code	
SAN FRANCISCO	CALIFORNIA		94080	

Relationship: Executive Officer	Director	Promoter
---------------------------------	----------	----------

Clarification of Response (if Necessary)

Last Name	First Name	Middle Name
Akers	Joseph	A.
Street Address 1	Street Address 2	
400 OYSTER POINT BLVD	SUITE 505	
City	State/Province/Country	ZIP/Postal Code
SAN FRANCISCO	CALIFORNIA	94080
Relationship: Execut	ive Officer Director	Promoter

Clarification of Response (if Necessary)

First Name	Middle Name
M.	David
Street	Address 2
SUIT	'E 505
State/Province/Country	ZIP/Postal Code
CALIFORNIA	94080
tive Officer Dir	ector 🔽 Promoter
	M. Street

Clarification of Response (if Necessary)

Last Name	First Name		Middle Name
McNab, Jr.	James		R.
Street Address 1	1	Street Address 2	]
400 OYSTER POINT BLVD		SUITE 505	
City	State/Province/Cour	ntry	ZIP/Postal Code
SAN FRANCISCO	CALIFORNIA		94080
Relationship: Execut	tive Officer	Director	Promoter
Clarification of Response (if Necessary	i)		

4. Industry Group

# C Agriculture

## **Banking & Financial Services**

- C Commercial Banking
- C Insurance
- C Investing
- C Investment Banking

C Pooled Investment Fund

Other Banking & Financial C Services

## C Business Services

## Energy

- C Coal Mining
- C Electric Utilities
- C Energy Conservation
- C Environmental Services
- C Oil & Gas
- C Other Energy

## C Retailing

- C Restaurants Health Insurance
- C Other Health Care

Health Care

C Manufacturing

**Real Estate** 

0

0

C Commercial

C Residential

Construction

**O** Other Real Estate

**REITS & Finance** 

0

C

0

0

C Biotechnology

Pharmaceuticals

# 5. Issuer Size

## **Revenue Range**

### C No Revenues

- C \$1 - \$1,000,000
- C \$1,000,001 - \$5,000,000
- C \$5,000,001 - \$25,000,000
- \$25,000,001 \$100,000,000 C
- C Over \$100,000,000
- $\odot$ Decline to Disclose
- C Not Applicable

- Aggregate Net Asset Value Range
  - No Aggregate Net Asset Value
- C \$1 - \$5,000,000
- C \$5,000,001 - \$25,000,000
  - \$25,000,001 \$50,000,000
- C \$50,000,001 - \$100,000,000
- C Over \$100.000.000
- C Decline to Disclose
- 0 Not Applicable

## 6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply) Rule 504(b)(1) (not (i), (ii) Rule 505 Г or (iii)) Rule 506(b) Rule 504 (b)(1)(i) Rule 504 (b)(1)(ii) Rule 506(c) г



7.	Type of Fil	ling		
•	New Notice	Date of First Sale	2022-02-04	First Sale Yet to Occur

Amendment

# 8. Duration of Offering

Does the Issuer intend this offering to last more than one year?

C Yes C No

### Type(s) of Securities Offered (select all that apply) 9.

	Pooled Investment Fund	<b>F</b>	Equity
1	Interests		Equity

- Tenant-in-Common Securities Debt Option, Warrant or Other Right to
- Mineral Property Securities Acquire Another Security

# Hospitals & Physicians

# Technology

## C Computers

- C Telecommunications
- C Other Technology

## Travel

- C Airlines & Airports
- C Lodging & Conventions
- C Tourism & Travel Services
- C Other Travel

## C Other

Sec	urity	to	be	Acq	uired	Upon

•	Exercise of Option, Warrant or Other Right to Acquire	Γ	Other (describe)
	Security		

10. Business Combination Transa	ction
Is this offering being made in connection with a business c transaction, such as a merger, acquisition or exchange offer	
Clarification of Response (if Necessary)	
11. Minimum Investment	
Minimum investment accepted from any outside \$	USD
12. Sales Compensation	
Recipient	Recipient CRD Number 🔲 None
Maxim Group LLC	120708
(Associated) Broker or Dealer 🔽 None	(Associated) Broker or Dealer CRD 😿 None
Street Address 1	Street Address 2
300 PARK AVE	16TH FLOOR
City State	e/Province/Country ZIP/Postal Code
NEW YORK	EW YORK 10022
State(s) of Solicitation 🔲 All States 🔲 Fo	reign/Non-US
NEW YORK	

13. Offering and	Sales Amounts
------------------	---------------

Total Offering Amount	\$ 7019570	USD	Indefinite
Total Amount Sold	\$ 1520669	USD	
Total Remaining to be Sold	\$ 5498901	USD	Indefinite

Clarification of Response (if Necessary)

Offering amount represents 1,289,796 Pre-Funded Warrants and 4,664,038 Placement Warrants at a combined purchase price of \$1.179 per warrant. Amount sold represents 1,289,796 Pre-Funded warrants.

14.	nvestors
-----	----------

 $\Box$ 

Select if securities in the offering have been or may be sold to persons who	
do not qualify as accredited investors,	
Number of such non-accredited investors who already have invested in the	
offering	

Regardless of whether securities in the offering have been or may be sold
to persons who do not qualify as accredited investors, enter the total
number of investors who already have invested in the offering:

1		 
	1	

15. Sales Commissions & Finders' Fees Expenses

Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions	\$ 106447	USD	Estimate			
Finders' Fees	\$ 0	USD	Estimate			
larification of Response (if Necessary)						

# 16. Use of Proceeds

C

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

	\$ 0	USD	Estimate
Clarification of Response (if Necessary)			

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

**Terms of Submission** 

In submitting this notice, each Issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities
  described and undertaking to furnish them, upon written request, the information furnished to
  offerees.
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which the issuer maintains its principal place of business or any State in which the state in which the state in which the issuer maintains its principal place of business or any State in which the issuer maintains its principal place of business or any State in which the state in which the state in which the issuer maintains is principal place of business or any State in which the issuer maintains is principal place of business or any State in which the issuer maintains is principal place of business or any State in which the issuer maintains is principal place of business or any State in which the issuer maintains is principal place of business or any State in which the issuer maintains is principal place of business or any Stat
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
TITAN PHARMACEUTIC INC	ALS /s/ Kate Beebe DeVarney, Ph.I	Kate Beebe D. DeVarney, Ph.D.	President and COO	2022-02-07